Abstract

This report summarizes the results of the first phase of VTT's PreMed project. It provides an overview of the Finnish precision medicine landscape and business opportunities opened by secondary use of health related data as enabled by biobanks and other data sources. The observations are based on openly available information and interviews of key stakeholders. The report describes the Finnish infrastructure supporting secondary use and covers the existing entities (e.g. biobanks), entities currently in development (e.g. the Service Operator and Genome Center) and related national activities, most notably the FinnGen project. It is concluded that the Finnish infrastructure is well-developed and internationally competent, but there are worries among the stakeholders concerning the delays in setting up the components under development. Analysis of international developments reveals that a large number of efforts is on-going targeted at collecting genome data, supporting co-operation and improving access to data and processing tools. Although the international market potential is high, most Finnish SME's in the precision medicine domain still have difficulties in generating profitable business. The related reasons and bottlenecks are analysed and new business opportunities are analysed in the report. The potential of Artificial Intelligence is specifically addressed as a technology powered by the increased availability of health data for secondary use. The report provides an analysis of business opportunities in four areas covering new therapy development, health risk assessment and diagnostics, therapy selection and direct-to-consumer genomics. The analysis provides policies and strategies, which should be adopted to remove the main barriers. It is widely understood that successful business in data-driven precision medicine relies on networked stakeholders. In order to understand the mechanisms of the business ecosystem an initial ecosystem model has been constructed in the PreMed project. The model enables simulation of different alternative development paths for the precision medicine ecosystem. The report forms the basis for further work planned to be carried out in the PreMed project, which is scheduled to be completed by April 2020.
Original languageEnglish
PublisherVTT Technical Research Centre of Finland
Number of pages74
Publication statusPublished - 29 Aug 2018
MoE publication typeNot Eligible

Publication series

NameResearch Report
PublisherVTT
No.VTT-R-03318-18

Fingerprint

medicine
stakeholder
ecosystem
genome
infrastructure
artificial intelligence
health risk
need
genomics
risk assessment
market
project
simulation
analysis
health
therapy

Keywords

  • precision medicine
  • personalized medicine
  • secondary use
  • artificial intelligence
  • genome technology
  • biobank
  • business ecosystem

Cite this

@book{a9a445fa9893412e8ddf5b3a2adf36c3,
title = "Data-driven precision medicine ecosystem - stakeholder needs and opportunities",
abstract = "This report summarizes the results of the first phase of VTT's PreMed project. It provides an overview of the Finnish precision medicine landscape and business opportunities opened by secondary use of health related data as enabled by biobanks and other data sources. The observations are based on openly available information and interviews of key stakeholders. The report describes the Finnish infrastructure supporting secondary use and covers the existing entities (e.g. biobanks), entities currently in development (e.g. the Service Operator and Genome Center) and related national activities, most notably the FinnGen project. It is concluded that the Finnish infrastructure is well-developed and internationally competent, but there are worries among the stakeholders concerning the delays in setting up the components under development. Analysis of international developments reveals that a large number of efforts is on-going targeted at collecting genome data, supporting co-operation and improving access to data and processing tools. Although the international market potential is high, most Finnish SME's in the precision medicine domain still have difficulties in generating profitable business. The related reasons and bottlenecks are analysed and new business opportunities are analysed in the report. The potential of Artificial Intelligence is specifically addressed as a technology powered by the increased availability of health data for secondary use. The report provides an analysis of business opportunities in four areas covering new therapy development, health risk assessment and diagnostics, therapy selection and direct-to-consumer genomics. The analysis provides policies and strategies, which should be adopted to remove the main barriers. It is widely understood that successful business in data-driven precision medicine relies on networked stakeholders. In order to understand the mechanisms of the business ecosystem an initial ecosystem model has been constructed in the PreMed project. The model enables simulation of different alternative development paths for the precision medicine ecosystem. The report forms the basis for further work planned to be carried out in the PreMed project, which is scheduled to be completed by April 2020.",
keywords = "precision medicine, personalized medicine, secondary use, artificial intelligence, genome technology, biobank, business ecosystem",
author = "Jaakko L{\"a}hteenm{\"a}ki and Mari Ervasti and Richard Fagerstr{\"o}m and {van Gils}, Mark and Juha Pajula and Sampsa Ruutu and Anton Sigfrids and Ville Valovirta and Peter Yl{\'e}n",
year = "2018",
month = "8",
day = "29",
language = "English",
series = "Research Report",
publisher = "VTT Technical Research Centre of Finland",
number = "VTT-R-03318-18",
address = "Finland",

}

Data-driven precision medicine ecosystem - stakeholder needs and opportunities. / Lähteenmäki, Jaakko; Ervasti, Mari; Fagerström, Richard; van Gils, Mark; Pajula, Juha; Ruutu, Sampsa; Sigfrids, Anton; Valovirta, Ville; Ylén, Peter.

VTT Technical Research Centre of Finland, 2018. 74 p. (VTT Research Report; No. VTT-R-03318-18).

Research output: Book/ReportReportProfessional

TY - BOOK

T1 - Data-driven precision medicine ecosystem - stakeholder needs and opportunities

AU - Lähteenmäki, Jaakko

AU - Ervasti, Mari

AU - Fagerström, Richard

AU - van Gils, Mark

AU - Pajula, Juha

AU - Ruutu, Sampsa

AU - Sigfrids, Anton

AU - Valovirta, Ville

AU - Ylén, Peter

PY - 2018/8/29

Y1 - 2018/8/29

N2 - This report summarizes the results of the first phase of VTT's PreMed project. It provides an overview of the Finnish precision medicine landscape and business opportunities opened by secondary use of health related data as enabled by biobanks and other data sources. The observations are based on openly available information and interviews of key stakeholders. The report describes the Finnish infrastructure supporting secondary use and covers the existing entities (e.g. biobanks), entities currently in development (e.g. the Service Operator and Genome Center) and related national activities, most notably the FinnGen project. It is concluded that the Finnish infrastructure is well-developed and internationally competent, but there are worries among the stakeholders concerning the delays in setting up the components under development. Analysis of international developments reveals that a large number of efforts is on-going targeted at collecting genome data, supporting co-operation and improving access to data and processing tools. Although the international market potential is high, most Finnish SME's in the precision medicine domain still have difficulties in generating profitable business. The related reasons and bottlenecks are analysed and new business opportunities are analysed in the report. The potential of Artificial Intelligence is specifically addressed as a technology powered by the increased availability of health data for secondary use. The report provides an analysis of business opportunities in four areas covering new therapy development, health risk assessment and diagnostics, therapy selection and direct-to-consumer genomics. The analysis provides policies and strategies, which should be adopted to remove the main barriers. It is widely understood that successful business in data-driven precision medicine relies on networked stakeholders. In order to understand the mechanisms of the business ecosystem an initial ecosystem model has been constructed in the PreMed project. The model enables simulation of different alternative development paths for the precision medicine ecosystem. The report forms the basis for further work planned to be carried out in the PreMed project, which is scheduled to be completed by April 2020.

AB - This report summarizes the results of the first phase of VTT's PreMed project. It provides an overview of the Finnish precision medicine landscape and business opportunities opened by secondary use of health related data as enabled by biobanks and other data sources. The observations are based on openly available information and interviews of key stakeholders. The report describes the Finnish infrastructure supporting secondary use and covers the existing entities (e.g. biobanks), entities currently in development (e.g. the Service Operator and Genome Center) and related national activities, most notably the FinnGen project. It is concluded that the Finnish infrastructure is well-developed and internationally competent, but there are worries among the stakeholders concerning the delays in setting up the components under development. Analysis of international developments reveals that a large number of efforts is on-going targeted at collecting genome data, supporting co-operation and improving access to data and processing tools. Although the international market potential is high, most Finnish SME's in the precision medicine domain still have difficulties in generating profitable business. The related reasons and bottlenecks are analysed and new business opportunities are analysed in the report. The potential of Artificial Intelligence is specifically addressed as a technology powered by the increased availability of health data for secondary use. The report provides an analysis of business opportunities in four areas covering new therapy development, health risk assessment and diagnostics, therapy selection and direct-to-consumer genomics. The analysis provides policies and strategies, which should be adopted to remove the main barriers. It is widely understood that successful business in data-driven precision medicine relies on networked stakeholders. In order to understand the mechanisms of the business ecosystem an initial ecosystem model has been constructed in the PreMed project. The model enables simulation of different alternative development paths for the precision medicine ecosystem. The report forms the basis for further work planned to be carried out in the PreMed project, which is scheduled to be completed by April 2020.

KW - precision medicine

KW - personalized medicine

KW - secondary use

KW - artificial intelligence

KW - genome technology

KW - biobank

KW - business ecosystem

M3 - Report

T3 - Research Report

BT - Data-driven precision medicine ecosystem - stakeholder needs and opportunities

PB - VTT Technical Research Centre of Finland

ER -

Lähteenmäki J, Ervasti M, Fagerström R, van Gils M, Pajula J, Ruutu S et al. Data-driven precision medicine ecosystem - stakeholder needs and opportunities. VTT Technical Research Centre of Finland, 2018. 74 p. (VTT Research Report; No. VTT-R-03318-18).